Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.75 | — | 14.38 | — | 9.58 | 11.86 | 12.13 | 92.25 | 9.28 | 1665.48 | 12.67 | — | — | 22.49 | 10.54 | 14.74 | 7.25 | 7.57 | 9.43 | 25.09 | 7.53 |
| — | — | +18.6% | — | +3.3% | -99.3% | -4.2% | — | — | +7304.7% | +20.2% | — | — | +197.3% | +11.8% | -41.3% | -3.7% | -22.2% | -10.5% | -59.2% | -77.0% | |
| P/S Ratio | 2.69 | 2.30 | 2.68 | 2.02 | 2.04 | 2.35 | 2.62 | 2.13 | 2.34 | 3.00 | 2.66 | 2.79 | 3.47 | 4.03 | 3.16 | 3.03 | 2.76 | 2.69 | 2.89 | 3.57 | 2.56 |
| — | -2.3% | +2.2% | -5.3% | -13.0% | -21.5% | -1.2% | -23.7% | -32.5% | -25.5% | -15.9% | -7.9% | +25.6% | +49.6% | +9.2% | -15.2% | +8.1% | -9.8% | -18.3% | -20.2% | -45.4% | |
| P/B Ratio | 1.94 | 1.62 | 1.71 | 1.63 | 1.46 | 1.55 | 1.59 | 1.71 | 1.79 | 1.81 | 1.71 | 1.82 | 1.93 | 2.11 | 2.31 | 3.07 | 2.69 | 3.42 | 3.59 | 4.40 | 3.24 |
| — | +4.4% | +7.9% | -4.6% | -18.7% | -14.4% | -7.0% | -6.1% | -6.9% | -14.2% | -26.0% | -40.7% | -28.5% | -38.2% | -35.7% | -30.2% | -16.7% | +6.5% | +20.3% | +33.9% | +10.1% | |
| P/FCF | 18.58 | 114.59 | 17.78 | 7.86 | 8.48 | — | 20.32 | 6.52 | 6.84 | — | 102.39 | 9.69 | 17.69 | — | 789.40 | 9.70 | 12.19 | 10.07 | 12.59 | 17.30 | 6.02 |
| — | — | -12.5% | +20.6% | +24.0% | — | -80.2% | -32.7% | -61.3% | — | -87.0% | -0.2% | +45.2% | — | +6171.8% | -43.9% | +102.4% | +92.1% | -2.4% | +44.1% | -80.5% | |
| EV / EBITDA | 11.55 | 8.51 | 10.44 | 9.67 | 9.41 | 9.53 | 8.16 | 7.12 | 8.61 | 15.72 | 8.98 | 141.63 | — | 17.35 | 8.15 | 11.97 | 6.54 | 5.95 | 7.34 | 20.61 | 7.76 |
| — | -10.6% | +27.9% | +35.9% | +9.3% | -39.4% | -9.1% | -95.0% | — | -9.4% | +10.2% | +1083.5% | — | +191.5% | +11.1% | -41.9% | -15.8% | -33.4% | -27.0% | -31.7% | -54.4% | |
| EV / EBIT | 15.21 | 3582.98 | 14.18 | — | 12.30 | 13.40 | 14.82 | 15.95 | 10.53 | 84.20 | 13.42 | — | — | 24.50 | 10.11 | 14.82 | 7.64 | 7.16 | 8.79 | 22.68 | 8.64 |
| — | +26642.1% | -4.3% | — | +16.9% | -84.1% | +10.4% | — | — | +243.6% | +32.7% | — | — | +242.3% | +15.0% | -34.7% | -11.5% | -20.3% | -12.4% | -66.7% | -87.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.3% | 72.8% | 67.3% | 70.0% | 74.9% | 64.3% | 71.7% | 73.0% | 60.8% | 62.1% | 70.6% | 41.0% | 21.4% | 64.7% | 67.8% | 55.1% | 69.1% | 67.3% | 57.9% | 55.2% | 54.8% |
| — | +13.2% | -6.1% | -4.2% | +23.2% | +3.6% | +1.6% | +77.9% | +184.2% | -4.0% | +4.0% | -25.5% | -69.0% | -3.9% | +17.1% | -0.1% | +26.1% | +15.1% | -11.7% | -19.1% | -24.1% | |
| Operating Margin | 24.7% | 31.3% | 27.9% | 21.0% | 21.3% | 24.4% | 33.7% | 32.2% | 28.1% | 14.1% | 30.6% | -8.7% | -22.3% | 18.1% | 36.2% | 22.0% | 42.8% | 46.7% | 39.1% | 13.8% | 32.2% |
| — | +28.3% | -17.2% | -34.8% | -24.0% | +72.5% | +10.0% | +471.8% | +226.0% | -21.7% | -15.3% | -139.4% | -152.0% | -61.3% | -7.6% | +60.0% | +32.9% | +47.3% | +18.1% | +73.8% | +32.6% | |
| Net Margin | 12.4% | -1.6% | 18.6% | -9.4% | 21.3% | 19.9% | 21.6% | 2.3% | 25.3% | 0.2% | 21.0% | -22.9% | -17.7% | 17.9% | 30.0% | 20.6% | 38.1% | 35.6% | 30.7% | 14.2% | 33.9% |
| — | -108.2% | -14.0% | -513.7% | -15.9% | +10890.3% | +3.2% | +109.9% | +242.4% | -99.0% | -30.1% | -211.6% | -146.5% | -49.7% | -2.3% | +44.4% | +12.3% | +16.0% | -8.7% | +95.5% | +137.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 8.9% | -0.3% | 3.0% | -1.8% | 3.9% | 3.2% | 3.3% | 0.4% | 5.0% | 0.0% | 3.4% | -3.6% | -2.4% | 2.3% | 5.6% | 5.3% | 9.6% | 11.6% | 9.8% | 4.4% | 11.2% |
| — | -108.6% | -8.4% | -511.6% | -21.5% | +12079.3% | -3.5% | +112.4% | +303.4% | -98.9% | -39.0% | -167.8% | -125.5% | -80.0% | -42.8% | +19.6% | -14.2% | +39.2% | +33.4% | +236.7% | +393.8% | |
| ROA | 3.7% | -0.1% | 1.3% | -0.8% | 1.7% | 1.4% | 1.4% | 0.2% | 2.1% | 0.0% | 1.4% | -1.5% | -1.1% | 1.1% | 2.8% | 2.5% | 4.4% | 5.2% | 4.3% | 1.9% | 4.7% |
| — | -108.6% | -8.2% | -524.6% | -16.9% | +12676.4% | +1.0% | +112.3% | +286.6% | -99.0% | -50.6% | -159.5% | -124.9% | -78.5% | -34.5% | +35.2% | -5.5% | +47.6% | +38.3% | +270.1% | +467.8% | |
| ROIC | 7.5% | 2.3% | 2.0% | 1.8% | 1.8% | 1.8% | 2.3% | 2.8% | 2.4% | 0.9% | 2.2% | -0.6% | -1.4% | 1.2% | 3.8% | 3.1% | 5.8% | 8.1% | 6.6% | 2.2% | 5.3% |
| — | +31.1% | -14.1% | -35.0% | -25.9% | +100.7% | +6.9% | +561.7% | +268.4% | -25.2% | -43.3% | -119.3% | -124.4% | -85.3% | -42.6% | +42.4% | +8.3% | +90.0% | +88.1% | +256.9% | +257.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.78 | 0.74 | 0.71 | 0.78 | 0.66 | 0.69 | 0.68 | 0.72 | 0.72 | 0.78 | 0.74 | 0.79 | 0.65 | 0.66 | 0.35 | 0.36 | 0.38 | 0.45 | 0.42 | 0.48 | 0.51 |
| — | +6.5% | +5.4% | +8.0% | -7.9% | -11.1% | -8.9% | -9.4% | +10.0% | +18.6% | +115.2% | +118.3% | +70.3% | +47.1% | -18.6% | -23.9% | -24.0% | -16.6% | -23.6% | -20.8% | -46.2% | |
| Debt / EBITDA | 3.31 | 10.73 | 12.36 | 12.54 | 11.84 | 11.88 | 9.82 | 8.47 | 9.91 | 19.02 | 10.91 | 174.07 | — | 16.65 | 4.27 | 5.08 | 3.28 | 2.77 | 3.12 | 8.12 | 4.22 |
| — | -9.7% | +25.9% | +48.1% | +19.5% | -37.5% | -10.0% | -95.1% | — | +14.2% | +155.4% | +3329.0% | — | +500.9% | +36.9% | -37.5% | -22.4% | -46.4% | -50.8% | -57.0% | -74.5% | |
| Current Ratio | 1.16 | 1.27 | 1.25 | 1.16 | 1.28 | 1.16 | 1.26 | 1.17 | 1.00 | 0.86 | 1.05 | 0.91 | 2.38 | 2.12 | 1.37 | 1.22 | 1.59 | 1.42 | 1.39 | 1.40 | 1.39 |
| — | +9.4% | -0.9% | -1.0% | +28.2% | +34.2% | +20.1% | +29.2% | -57.9% | -59.2% | -23.5% | -25.5% | +49.6% | +48.8% | -1.2% | -13.0% | +14.7% | +4.0% | -6.6% | +3.4% | -0.9% | |
| Quick Ratio | 0.87 | 0.96 | 0.94 | 0.87 | 0.97 | 0.85 | 0.96 | 0.92 | 0.73 | 0.60 | 0.78 | 0.69 | 2.05 | 1.82 | 1.11 | 1.00 | 1.37 | 1.20 | 1.13 | 1.19 | 1.18 |
| — | +13.3% | -2.5% | -5.1% | +32.9% | +41.1% | +23.4% | +32.5% | -64.4% | -66.9% | -29.8% | -30.9% | +49.1% | +51.3% | -2.0% | -15.4% | +16.6% | +7.6% | -2.8% | +13.8% | +4.7% | |
| Interest Coverage | 3.82 | 0.02 | 5.75 | -1.31 | 6.11 | 5.65 | 5.26 | 4.54 | 7.02 | 0.87 | 5.33 | -4.99 | -3.82 | 5.47 | 20.72 | 17.72 | 29.94 | 40.06 | 29.11 | 13.15 | 25.13 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PFE stock.
Pfizer Inc.'s current P/E is 21.8x. The average P/E over the last 2 quarters is 12.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pfizer Inc.'s current operating margin is 24.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pfizer Inc.'s business trajectory between earnings reports.